Multiple myeloma is a relatively rare form of cancer that affects plasma cells in the bone marrow. It accounts for approximately 1% of all cancers and 10% of all hematologic malignancies. The prevalence of multiple myeloma varies across different regions and populations, with higher rates observed in developed countries. It primarily affects older individuals, with the median age at diagnosis being around 70 years. Although it is not a common cancer, it is important to raise awareness about multiple myeloma and its potential impact on patients' lives.
Multiple myeloma is a relatively rare form of cancer that affects plasma cells, a type of white blood cell found in the bone marrow. It is the second most common blood cancer, accounting for approximately 1% of all cancers and 10% of all hematologic malignancies. Although it is considered a rare disease, its prevalence has been increasing over the years.
According to the American Cancer Society, an estimated 32,270 new cases of multiple myeloma will be diagnosed in the United States in 2020. The disease is slightly more common in men than in women, and the risk of developing multiple myeloma increases with age. The median age at diagnosis is around 69 years.
While multiple myeloma is not as prevalent as some other cancers, it is important to note that it can have a significant impact on individuals and their families. Early detection, improved treatment options, and ongoing research efforts are crucial in managing and combating this disease.